Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue

Brain, Behavior, and Immunity

Volumn 25, Issue 6, 2011, Pages 1094-1098

  Felger, Jennifer C ^a,b   Alagbe, Oyetunde ^c   Pace, Thaddeus W W ^a,b   Woolwine, Bobbi J ^a,b   Hu, Fang ^a,b   Raison, Charles L ^a,b   Miller, Andrew H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Newport Integrated Behavioral Hospital Inc   (United States)

Author keywords

Cortisol; Cytokines; Depression; Fatigue; Flow cytometry; Innate immunity; Interferon alpha; P38 Mitogen activated protein kinase

Indexed keywords

ALPHA INTERFERON; CORTICOTROPIN; HYDROCORTISONE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATIONAL STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INDUCTION; FATIGUE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANTIVIRAL AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; FATIGUE; HEPATITIS C, CHRONIC; HUMANS; HYDROCORTISONE; IMMUNITY, INNATE; INTERFERON-ALPHA; INTERLEUKIN-6; LYMPHOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79960249622     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.02.015     Document Type: Article

References (27)

1. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14(12):1095-1104.
2. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 2003, 160(7):1342-1345.
3. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9(1):46-56.
4. First MB, Spitzer RL, Gibbon M, and Williams JB. 1997. Structured Clinical Interview for DSM-IV: Washington DC: American Psychiatric Press.
5. Friebe A., Schwarz M.J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., Janssen G., Schaefer M. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J. Immunother. 2007, 30(3):333-337.
6. Gibb J., Hayley S., Gandhi R., Poulter M.O., Anisman H. Synergistic and additive actions of a psychosocial stressor and endotoxin challenge: Circulating and brain cytokines, plasma corticosterone and behavioral changes in mice. Brain Behav. Immun. 2008, 22(4):573-589.
7. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374(Pt 1):1-20.
8. Hu F., Pace T.W., Miller A.H. Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav. Immun. 2009, 23(4):455-463.
9. Johnson J.D., O'Connor K.A., Deak T., Stark M., Watkins L.R., Maier S.F. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav. Immun. 2002, 16(4):461-476.
10. Kearns N.P., Cruickshank C.A., McGuigan K.J., Riley S.A., Shaw S.P., Snaith R.P. A comparison of depression rating scales. Br. J. Psychiatry 1982, 141:45-49.
11. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 2009, 65(4):344-348.
12. Lotrich F.E., Rabinovitz M., Gironda P., Pollock B.G. Depression following pegylated interferon-alpha: characteristics and vulnerability. J. Psychosom. Res. 2007, 63(2):131-135.
13. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65(9):732-741.
14. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
15. Potter G.G., Kittinger J.D., Wagner H.R., Steffens D.C., Krishnan K.R. Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 2004, 29(12):2266-2271.
16. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 2009, 23(8):1109-1116.
17. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65(4):296-303.
18. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 2010, 15(5):535-547.
19. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, and Miller AH. 2010b. Chronic Interferon-Alpha Administration Disrupts Sleep Continuity and Depth in Patients with Hepatitis C: Association with Fatigue, Motor Slowing, and Increased Evening Cortisol. Biol. Psychiatry.
20. Rius C., Abu-Taha M., Hermenegildo C., Piqueras L., Cerda-Nicolas J.M., Issekutz A.C., Estan L., Cortijo J., Morcillo E.J., Orallo F., et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappaB activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol. 2010, 185(6):3718-3727.
21. Sanchez M.M., Alagbe O., Felger J.C., Zhang J., Graff A.E., Grand A.P., Maestripieri D., Miller A.H. Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys. Mol. Psychiatry 2007, 12(10):895-897.
22. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39(3):315-325.
23. Wang X., Wu H., Miller A.H. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol. Psychiatry 2004, 9(1):65-75.
24. Wichers M.C., Kenis G., Leue C., Koek G., Robaeys G., Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol. Psychiatry 2006, 60(1):77-79.
25. Zampieri C.A., Fortin J.F., Nolan G.P., Nabel G.J. The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J. Virol. 2007, 81(3):1230-1240.
26. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31(10):2121-2131.
27. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35(13):2510-2520.